Clinical Trial Update: Study of GC1008 in Patients With Idiopathic Pulmonary Fibrosis (IPF) [Phase 1]

View source ↗

Summary

This update reports the completion of a Phase 1 study of GC1008 (fresolimumab) in patients with Idiopathic Pulmonary Fibrosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• GC1008 (fresolimumab)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Idiopathic Pulmonary Fibrosis | Phase 1 | Status: COMPLETED